Last updated on November 2017

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects with Pulmonary Hypertension (PH) in Heart Failure with Preserved Ejection Fraction (HFpEF)


Brief description of study

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects with Pulmonary Hypertension (PH) in Heart Failure with Preserved Ejection Fraction (HFpEF)

Detailed Study Description

The primary objective of this study is to assess the effect of oral treprostinil compared with placebo on change in exercise capacity as measured by change in 6MWD from Baseline to Week 24 in subjects with PH associated with HFpEF. There are no approved treatments for PH in subjects with left heart disease; however, the efficacy of therapies in WHO Group 1 PAH, along with lack of evidence-based therapies available for the treatment of HFpEF, have stimulated further investigation in this indication.

Clinical Study Identifier: TX15072

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Kathleen McNulty, MHS, CCRC

The Lung Research Center
Chesterfield, MO USA
  Connect »